Skip to Content

Bladder Cancer: Avelumab Maintenance Shows Benefit for Both Patients With and Without Diabetes Mellitus

In this MEDtalk, Dr. Petros Grivas presents the long-term outcomes from the JAVELIN Bladder 100 trial, discussing the impact of avelumab as first-line maintenance therapy for advanced urothelial carcinoma in patients with and without diabetes.

Petros Grivas

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top